4D Molecular Therapeutics, Inc. Board of Directors

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Dr. David H. Kirn M.D.

Dr. David H. Kirn M.D.

Co-Founder, CEO & Director

Dr. An Song Ph.D.

Dr. An Song Ph.D.

Chief Development Officer

Mr. Uneek Mehra

Mr. Uneek Mehra

Chief Financial & Business Officer

Ms. Theresa Janke

Ms. Theresa Janke

Co-Founder & Chief of Staff

Dr. Scott P. Bizily J.D., Ph.D.

Dr. Scott P. Bizily J.D., Ph.D.

Chief Legal Officer & Corporate Secretary

Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.

Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.

Senior VP & Therapeutic Area Head of Pulmonology

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.